Terms: = Lymphoma AND PRKAR1A, DKFZp779L0468, 5573, ENSG00000108946, PRKAR1, P10644, CNC1, PKR1, MGC17251, PPNAD1, TSE1, CNC, CAR AND Prognosis
259 results:
1. Sequential CD7 car T-Cell Therapy and Allogeneic HSCT without GVHD Prophylaxis.
Hu Y; Zhang M; Yang T; Mo Z; Wei G; Jing R; Zhao H; Chen R; Zu C; Gu T; Xiao P; Hong R; Feng J; Fu S; Kong D; Xu H; Cui J; Huang S; Liang B; Yuan X; Cui Q; Guo H; Yu Y; Feng Y; Jin C; Ren J; Chang AH; Wang D; Huang H
N Engl J Med; 2024 Apr; 390(16):1467-1480. PubMed ID: 38657244
[TBL] [Abstract] [Full Text] [Related]
2. Advancements in cancer immunotherapies targeting CD20: from pioneering monoclonal antibodies to chimeric antigen receptor-modified T cells.
Dabkowska A; Domka K; Firczuk M
Front Immunol; 2024; 15():1363102. PubMed ID: 38638442
[TBL] [Abstract] [Full Text] [Related]
3. [CHIMERIC ANTIGEN RECEPTOR T CELLS (car-T CELLS) THERAPY FOR B-CELL HEMATOLOGICAL MALIGNANCIES - FROM THE ISRAELI SOCIETY OF HEMATOLOGY AND TRANSFUSION MEDICINE].
Greenbaum U; Yehudai-Ofir D; Beyar Katz O; Shargian L; Jacoby E; Grisaru S; Zuckerman T; Ram R; Avigdor A
Harefuah; 2024 Apr; 163(4):236-243. PubMed ID: 38616634
[TBL] [Abstract] [Full Text] [Related]
4. A review of immunotargeted therapy for Philadelphia chromosome positive acute lymphoblastic leukaemia: making progress in chemotherapy-free regimens.
Xiong ZY; Shen YJ; Zhang SZ; Zhu HH
Hematology; 2024 Dec; 29(1):2335856. PubMed ID: 38581291
[TBL] [Abstract] [Full Text] [Related]
5. Empowering macrophages: the cancer fighters within the tumour microenvironment in mantle cell lymphoma.
Nylund P; Nikkarinen A; Ek S; Glimelius I
Front Immunol; 2024; 15():1373269. PubMed ID: 38566987
[TBL] [Abstract] [Full Text] [Related]
6. [Progress in treatment of primary mediastinal large B-cell lymphoma].
Chen LW; Li JY; Fan L
Zhonghua Xue Ye Xue Za Zhi; 2024 Jan; 45(1):98-102. PubMed ID: 38527847
[TBL] [Abstract] [Full Text] [Related]
7. Indicators describing the tumor lesion aggregation and dissemination and their impact on the prognosis of patients with diffuse large B cell lymphoma receiving chimeric antigen receptor T cell therapy.
Dang X; Li P; Shen A; Lu Y; Zhu Z; Zhang M; Qian W; Liang A; Zhang W
Cancer Med; 2024 Mar; 13(6):e6991. PubMed ID: 38506226
[TBL] [Abstract] [Full Text] [Related]
8. Matching-Adjusted Indirect Comparison of Brexucabtagene Autoleucel (ZUMA-2) and Pirtobrutinib (BRUIN) in Patients with Relapsed/Refractory Mantle Cell lymphoma Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor.
Salles G; Chen JMH; Zhang I; Kerbauy F; Wu JJ; Wade SW; Nunes A; Feng C; Kloos I; Peng W; Snider JT; Maciel D; Chan K; Keeping S; Shah B
Adv Ther; 2024 May; 41(5):1938-1952. PubMed ID: 38494543
[TBL] [Abstract] [Full Text] [Related]
9. Case report: Two pediatric cases of long-term leukemia-free survival with relapsed acute T-lymphoblastic leukemia treated with donor CD7 car-T cells bridging to haploidentical stem cell transplantation.
Song Y; Liu Z; Wang Q; Gao K; Wu T
Front Immunol; 2024; 15():1333037. PubMed ID: 38481998
[TBL] [Abstract] [Full Text] [Related]
10. [Clinical Analysis of Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia in Children].
Li TD; Hu SY; Zhai Z; Chen GH; Lu J; He HL; Xiao PF; Li J; Wang Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Feb; 32(1):78-84. PubMed ID: 38387903
[TBL] [Abstract] [Full Text] [Related]
11. [Clinical features and prognostic analysis of testicular relapse in pediatric acute lymphoblastic leukemia].
Wang N; Gao YY; Qi BQ; Ruan M; Lyu H; Zhang XY; Zhang RR; Liu TF; Chen YM; Zou Y; Guo Y; Yang WY; Zhang L; Zhu XF; Chen XJ
Zhonghua Er Ke Za Zhi; 2024 Mar; 62(3):262-267. PubMed ID: 38378289
[No Abstract] [Full Text] [Related]
12. Case report: The utilization of crizotinib and brentuximab vedotin as a bridge to autologous stem cell transplantation and followed by CD30-directed car-T cell therapy in relapsed/refractory ALK+ ALCL.
Liu W; Wu J; Ming X; Zhang Q; Zhou D; Zheng R; Zhou M; Shang Z; Chen L; Zhu X; Xiao Y
Front Immunol; 2024; 15():1346001. PubMed ID: 38375471
[TBL] [Abstract] [Full Text] [Related]
13. Chimeric antigen receptor T-cell therapy after COVID-19 in refractory high-grade B-cell lymphoma.
Hayashino K; Seike K; Fujiwara K; Kondo K; Matsubara C; Terao T; Kitamura W; Kamoi C; Fujiwara H; Asada N; Nishimori H; Ennishi D; Fujii K; Fujii N; Matsuoka KI; Maeda Y
Int J Hematol; 2024 Apr; 119(4):459-464. PubMed ID: 38349446
[TBL] [Abstract] [Full Text] [Related]
14. Treatment of secondary CNS lymphoma using CD19-targeted chimeric antigen receptor (car) T cells.
Kline K; Luetkens T; Koka R; Kallen ME; Chen W; Ahmad H; Omili D; Iraguha T; Gebru E; Fan X; Miller A; Dishanthan N; Baker JM; Dietze KA; Hankey KG; Yared JA; Hardy NM; Rapoport AP; Dahiya S; Atanackovic D
Cancer Immunol Immunother; 2024 Feb; 73(3):45. PubMed ID: 38349430
[TBL] [Abstract] [Full Text] [Related]
15. Long-term remission in a patient with relapsed Richter's transformation treated with CD19-directed chimeric antigen-receptor T-cells after allogeneic stem cell transplantation.
Kutsch N; Gödel P; Voltin CA; Hallek M; Scheid C; Borchmann P; Holtick U
Eur J Haematol; 2024 Jun; 112(6):984-987. PubMed ID: 38316549
[TBL] [Abstract] [Full Text] [Related]
16. Venetoclax plus dose-adjusted R-EPOCH (VR-DA-EPOCH) or G-EPOCH bridging to subsequent cellular therapy for the patients with transformed lymphoma a single center clinical experience.
Qin S; Jiang R; Dai L; Miao Y; Sha Y; Qiu T; Ding C; Wang Z; Shi C; Xia Y; Fan L; Xu W; Li J; Zhu H
Ann Hematol; 2024 May; 103(5):1635-1642. PubMed ID: 38246951
[TBL] [Abstract] [Full Text] [Related]
17. Current assessment and management of measurable residual disease in patients with acute lymphoblastic leukemia in the setting of car-T-cell therapy.
Lin M; Zhao X; Chang Y; Zhao X
Chin Med J (Engl); 2024 Jan; 137(2):140-151. PubMed ID: 38148315
[TBL] [Abstract] [Full Text] [Related]
18. Antitumor efficacy and safety of unedited autologous CD5.car T cells in relapsed/refractory mature T-cell lymphomas.
Hill LC; Rouce RH; Wu MJ; Wang T; Ma R; Zhang H; Mehta B; Lapteva N; Mei Z; Smith TS; Yang L; Srinivasan M; Burkhardt PM; Ramos CA; Lulla P; Arredondo M; Grilley B; Heslop HE; Brenner MK; Mamonkin M
Blood; 2024 Mar; 143(13):1231-1241. PubMed ID: 38145560
[TBL] [Abstract] [Full Text] [Related]
19. Case report: Differential diagnosis of highly amplified anti-CD5 car T cells and relapsed lymphoma cells in a patient with refractory ALK positive anaplastic large cell lymphoma.
Mu W; Zhang M; Hu G; Han Y; Mao X; Chen C; Shen K; Dai Z; Zhu X; Zhou X; Huang L; Ao Q; Xiao M
Front Immunol; 2023; 14():1280007. PubMed ID: 38143760
[TBL] [Abstract] [Full Text] [Related]
20. Whole-genome CRISPR screening identifies molecular mechanisms of PD-L1 expression in adult T-cell leukemia/lymphoma.
Chiba M; Shimono J; Suto K; Ishio T; Endo T; Goto H; Hasegawa H; Maeda M; Teshima T; Yang Y; Nakagawa M
Blood; 2024 Apr; 143(14):1379-1390. PubMed ID: 38142436
[TBL] [Abstract] [Full Text] [Related]
[Next]
